A Drug Interaction between Crizotinib and Warfarin in Non-Small-Cell Lung Cancer: A Case Report
Author:
Affiliation:
1. Section of Pharmaceutical Services, Nippon Medical School Hospital
2. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School
Publisher
Medical Association of Nippon Medical School
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jnms/84/6/84_291/_pdf
Reference10 articles.
1. 1. Wang C, Abe S, Matsuda K, Yu C, Li Y, Usuki J, Azuma A, Kudoh S: Effects of gefitinib on radiation-induced lung injury in mice. J Nippon Med Sch 2008; 75: 96-105.
2. 2. Li C, Gemma A, Minegishi Y, Matsuda K, Seike Y, Noro R, Shionoya A, Kawakami A, Ogawa N, Kudoh S: In vitro simulation study of individualized chemotherapy in lung cancer. J Nippon Med Sch 2007; 74: 217-222.
3. 3. Timm A, Kolesar JM: Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013; 70: 943-947.
4. 4. Segal EM, Flood MR, Mancini RS, Whiteman RT, Friedt GA, Kramer AR, Hofstetter MA: Oral Chemotherapy Food and Drug Interactions: A Comprehensive Review of the Literature. J Oncol Prac 2014; 10: e255-e268.
5. 5. Cropp JS, Bussey HI: A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 917-928.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Drug interactions between ALK inhibitors and warfarin with concurrent use of bucolome: a case report;Journal of Pharmaceutical Health Care and Sciences;2023-05-01
2. Interactions médicamenteuses des inhibiteurs de tyrosine kinase dans le traitement du cancer bronchique non à petites cellules;Bulletin du Cancer;2022-03
3. Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review;Drug Design, Development and Therapy;2020-04
Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review
4. SUPRATHERAPEUTIC PT-INR IN A PATIENT ON CRIZOTINIB FOR STAGE IV NON-SMALL CELL LUNG CANCER;Chest;2019-10
5. Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer;Clinical Pharmacokinetics;2018-06-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3